Jason Butler Analyst Performance

Managing Director at JMP Securities

Jason Butler is a stock analyst at JMP Securities focused in the medical sector, covering 33 publicly traded companies. Over the past year, Jason Butler has issued 21 stock ratings, including buy and hold recommendations. While full access to Jason Butler's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Butler's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 94 Last 10 Years
Buy Recommendations: 91.21% 83 Buy Ratings
Companies Covered: 33 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	91.2%	83 ratings
Hold	8.8%	8 ratings
Sell	0.0%	0 ratings

Out of 91 total stock ratings issued by Jason Butler at JMP Securities, the majority (91.2%) have been Buy recommendations, followed by 8.8% Hold.

Best & Worst Calls

Best Call
0000.0%
ESPR
Nov 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ESPR
Jun 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	90.9% of companies on NASDAQ	30 companies
OTCMKTS	3.0% of companies on OTCMKTS	1 company
NYSEAMERICAN	3.0% of companies on NYSEAMERICAN	1 company
NYSE	3.0% of companies on NYSE	1 company

Jason Butler, an analyst at JMP Securities, currently covers 33 companies listed on NASDAQ, OTCMKTS, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 31 companies	93.9%
	Computer and Technology 1 company	3.0%
	Miscellaneous 1 company	3.0%

Jason Butler of JMP Securities specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 16 companies	48.5%
PHARMACEUTICAL PREPARATIONS 9 companies	27.3%
MED - DRUGS 4 companies	12.1%
INTERNET SERVICES 1 company	3.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	3.0%
BIOTECHNOLOGY 1 company	3.0%
Miscellaneous 1 company	3.0%

About Jason Butler

Dr. Jason N. Butler is a Managing Director at Citizens JMP Securities LLC. He is covering the biotechnology industry. Prior to joining JMP Securities, he served as a Senior Associate Equity Analyst at Rodman & Renshaw covering biotechnology companies focused on therapies for metabolic and infectious diseases. Dr. Butler received his Bachelor’s degree in Biology and a PhD in Neuroscience from Imperial College London.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
PRTA Prothena	9/2/2025	Lower Price Target	$8.20	$11.00	Market Outperform
ABVX Abivax	7/23/2025	Boost Price Target	$10.00	$95.00	Market Outperform
ABVX Abivax	7/18/2025	Set Price Target	$10.34	$33.00
RAPP Rapport Therapeutics	7/8/2025	Reiterated Rating	$12.42	$28.00	Market Outperform
ACAD ACADIA Pharmaceuticals	6/26/2025	Reiterated Rating	$22.51	$37.00	Market Outperform
GHRS GH Research	6/24/2025	Reiterated Rating	$11.86	$39.00	Market Outperform
PGEN Precigen	6/12/2025	Reiterated Rating	$1.52	$6.00	Market Outperform
PRTA Prothena	5/27/2025	Lower Price Target	$6.58	$29.00	Market Outperform
VIGL Vigil Neuroscience	5/22/2025	Reiterated Rating	$7.92		Market Perform
ARGX argenex	5/14/2025	Set Price Target	$533.88	$699.00
TTD Trade Desk	5/9/2025	Lower Price Target	$72.98	$100.00	Market Outperform
PRTA Prothena	5/9/2025	Lower Price Target	$7.85	$78.00	Market Outperform
VRDN Viridian Therapeutics	5/7/2025	Lower Price Target	$12.29	$38.00	Market Outperform
ABVX Abivax	4/30/2025	Reiterated Rating	$7.32	$33.00	Market Outperform
CYTK Cytokinetics	4/10/2025	Reiterated Rating	$35.74	$78.00	Market Outperform
RAPP Rapport Therapeutics	4/8/2025	Initiated Coverage	$8.93	$28.00	Market Outperform
RZLT Rezolute	2/13/2025	Boost Price Target	$4.92	$9.00	Market Outperform
CYTK Cytokinetics	2/7/2025	Reiterated Rating	$43.66	$78.00	Market Outperform
ARGX argenex	1/14/2025	Boost Price Target	$670.40	$696.00	Market Outperform
CYTK Cytokinetics	1/14/2025	Reiterated Rating	$46.71	$78.00	Market Outperform
PGEN Precigen	1/14/2025	Reiterated Rating	$1.14	$5.00	Market Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.